Company intelligence / Profile preview

Mast MM

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Mast Therapeutics was a clinical-stage biopharmaceutical company primarily focused on developing novel therapies for serious orphan diseases, with a significant emphasis on sickle cell disease and heart failure. The company's lead candidate, vepoloxamer (MST-188), was a rheologic agent designed to improve microvascular blood flow by reducing viscosity and cell-to-cell adhesion. Following the failure of its Phase 3 EPIC trial in sickle cell disease in 2016, the company underwent a strategic shift. In 2017, Mast Therapeutics completed a reverse merger with Savara Inc., which subsequently focused on orphan lung diseases.

Therapeutic areas: HematologyCardiovascularOncology
Modalities: Small moleculePolymer-drug conjugate therapy
Industry: Biotech

Beyond the preview

Go deeper on Mast MM.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mast MM.

Explore the full profile